Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Under the decision, Medicare patients with inherited cancer mutations such as BRCA will receive coverage for NGS testing. Drugs that treat BRCA-mutated breast and ovarian cancers include AstraZeneca's Lynparza and Pfizer's Talzenna.
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Chinese cancer immunotherapy player BeiGene just filed a $100 IPO with the U.S. Securities Exchange Commission to advance its clinical pipeline of BTK, RAF and PARP inhibitors.